PT2575873E - Concentração de antigénios de vacinas com liofilização - Google Patents

Concentração de antigénios de vacinas com liofilização Download PDF

Info

Publication number
PT2575873E
PT2575873E PT117458273T PT11745827T PT2575873E PT 2575873 E PT2575873 E PT 2575873E PT 117458273 T PT117458273 T PT 117458273T PT 11745827 T PT11745827 T PT 11745827T PT 2575873 E PT2575873 E PT 2575873E
Authority
PT
Portugal
Prior art keywords
lyophilization
concentration
influenza vaccine
vaccine antigens
antigens
Prior art date
Application number
PT117458273T
Other languages
English (en)
Inventor
Kommareddy Sushma
Scampini Amanda
Baudner Barbara
O'hagan Derek
Singh Manmohan
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT2575873E publication Critical patent/PT2575873E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
PT117458273T 2010-06-01 2011-06-01 Concentração de antigénios de vacinas com liofilização PT2575873E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39672010P 2010-06-01 2010-06-01

Publications (1)

Publication Number Publication Date
PT2575873E true PT2575873E (pt) 2016-03-04

Family

ID=44503998

Family Applications (1)

Application Number Title Priority Date Filing Date
PT117458273T PT2575873E (pt) 2010-06-01 2011-06-01 Concentração de antigénios de vacinas com liofilização

Country Status (14)

Country Link
US (1) US20130243841A1 (pt)
EP (1) EP2575873B1 (pt)
JP (1) JP5976639B2 (pt)
KR (1) KR20130081659A (pt)
CN (1) CN102939104A (pt)
AU (1) AU2011262312B2 (pt)
BR (1) BR112012030616A2 (pt)
CA (1) CA2801151A1 (pt)
EA (1) EA201291404A1 (pt)
ES (1) ES2564096T3 (pt)
NZ (1) NZ603863A (pt)
PL (1) PL2575873T3 (pt)
PT (1) PT2575873E (pt)
WO (1) WO2011151726A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2808965C (en) * 2010-08-20 2020-01-07 Novartis Ag Soluble needle arrays for delivery of influenza vaccines
WO2012158483A2 (en) 2011-05-16 2012-11-22 Avery Dennison Corporation Adhesive containing microparticles
US20140322299A1 (en) * 2011-11-17 2014-10-30 Avery Dennison Corporation Controlled Release of Active Using pH
CN103242434B (zh) * 2012-02-08 2020-03-17 长春百克生物科技股份公司 无细胞百日咳疫苗的制备方法
CN105073934B (zh) 2013-02-07 2021-12-28 艾利丹尼森公司 具有改进性质的抗微生物粘合剂
CN105377293B (zh) 2013-03-14 2020-07-17 武田疫苗股份有限公司 减毒活甲病毒制剂的组合物和方法
US11213432B2 (en) 2013-03-15 2022-01-04 Avery Dennison Corporation Transparent cover dressing application system and inclusion of label strip
WO2015034924A1 (en) 2013-09-03 2015-03-12 Georgia Tech Research Corporation Thermally stable vaccine formulations and microneedles
EP3131918B1 (en) * 2014-04-16 2018-12-26 Hvidovre Hospital Development of methods for production of a whole hcv vaccine candidate stock
EP3789014A1 (en) 2014-06-05 2021-03-10 Avery Dennison Corporation Articles with active agent concentrated at the substrate contacting surface and related methods
US10280404B2 (en) 2014-10-28 2019-05-07 Hvidovre Hospital Optimized HCV full-length infectious cell culture systems and applications thereof
CN116057378A (zh) 2020-09-11 2023-05-02 富士胶片株式会社 浓缩器件、被检体液的浓缩方法、被检体液的检查方法、及检查试剂盒
CN114931557B (zh) * 2022-03-18 2023-07-07 辽宁成大生物股份有限公司 一种冻干保护剂、疫苗冻干制剂及其制备方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
CZ285050B6 (cs) 1991-03-01 1999-05-12 Minnesota Mining And Manufacturing Company 1-Substituované, 2-substituované-1H-imidazo/4,5-c /chinolin-4-aminy
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
PT733113E (pt) 1994-01-11 2007-08-10 Vlaams Interuniv Inst Biotech Vacina contra a gripe
CA2184132C (en) * 1995-09-21 2011-03-15 Kristina J. Hennessy An adjuvanted vaccine which is substantially free of non-host albumin
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
WO1998046262A1 (en) 1997-04-16 1998-10-22 Connaught Laboratories, Inc. Anti-influenza compositions supplemented with neuraminidase
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
BR0014281A (pt) 1999-09-24 2002-05-21 Smithkline Beecham Biolog Vacina contra vìrus de gripe intranasal
CA2401117C (en) 2000-03-03 2010-06-29 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
FR2808803B1 (fr) 2000-05-11 2004-12-10 Agronomique Inst Nat Rech Cellules es modifiees et gene specifique de cellules es
GB0017999D0 (en) * 2000-07-21 2000-09-13 Smithkline Beecham Biolog Novel device
DK1358319T3 (da) * 2000-09-25 2009-10-05 Polymun Scient Immunbio Forsch Levende influenzavaccine og fremgangsmåde til fremstilling heraf
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
US7803392B2 (en) 2000-12-27 2010-09-28 University Of Kentucky Research Foundation pH-Sensitive mucoadhesive film-forming gels and wax-film composites suitable for topical and mucosal delivery of molecules
EP2269639B1 (en) 2001-02-23 2018-11-28 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
JP2004536785A (ja) 2001-02-23 2004-12-09 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規なワクチン
AU2002254558A1 (en) * 2001-04-27 2002-11-11 Becton, Dickinson And Company Novel vaccine
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
WO2002101412A2 (en) * 2001-06-08 2002-12-19 Powderject Vaccines, Inc. Spray freeze-dried compositions
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
DE10144903A1 (de) 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Vermehrung von Viren in Zellkultur
FR2832423B1 (fr) 2001-11-22 2004-10-08 Vivalis Systeme d'expression de proteines exogenes dans un systeme aviaire
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
US6945952B2 (en) 2002-06-25 2005-09-20 Theraject, Inc. Solid solution perforator for drug delivery and other applications
US20050142139A1 (en) * 2003-03-21 2005-06-30 Norbert Schulke CD4-IgG2 formulations
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
KR20060135931A (ko) * 2004-04-01 2006-12-29 알자 코포레이션 인플루엔자 백신의 경피전달 장치 및 방법
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
MXPA06013490A (es) * 2004-05-19 2007-06-12 Johnson & Johnson Metodo y formulacion para el suministro transdermico de agentes inmunologicamente activos.
NZ551640A (en) 2004-05-20 2010-05-28 Id Biomedical Corp Process for the production of an influenza vaccine
PL2179744T3 (pl) 2004-09-09 2011-09-30 Novartis Ag Zmniejszanie potencjału zagrożeń działaniami jatrogennymi związanymi ze szczepionkami przeciwko grypie
DK2368975T3 (en) 2004-12-23 2015-01-05 Medimmune Llc Non-tumorigenic MDCK cell line for the propagation of viruses
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
CA2629393C (en) 2005-09-06 2014-06-10 Theraject, Inc. Solid solution perforator containing drug particle and/or drug-adsorbed particles
WO2007052163A2 (en) 2005-11-01 2007-05-10 Novartis Vaccines And Diagnostics Gmbh & Co Kg Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment
CA2627542A1 (en) 2005-11-18 2007-05-24 3M Innovative Properties Company Microneedle arrays and methods of preparing same
EP1948139A4 (en) 2005-11-18 2012-04-04 3M Innovative Properties Co COATING COMPOSITIONS, COATINGS DERIVED THEREFROM, AND MICRO-NETWORKS COMPRISING SUCH COATINGS
WO2007124393A2 (en) 2006-04-20 2007-11-01 3M Innovative Properties Company Molded articles comprising microneedle arrays
EA200900784A1 (ru) 2006-12-06 2009-12-30 Новартис Аг Вакцины, включающие антиген из четырех штаммов вируса гриппа
EP2185191B1 (en) 2007-06-27 2012-09-12 Novartis AG Low-additive influenza vaccines
WO2010002418A2 (en) 2008-07-01 2010-01-07 The Johns Hopkins University Quick-dissolving oral thin film for targeted delivery of therapeutic agents
RU2519193C2 (ru) * 2008-09-12 2014-06-10 Критикал Фармасьютикалс Лимитед Усовершенствование всасывания терапевтических средств через слизистые оболочки или кожу

Also Published As

Publication number Publication date
JP5976639B2 (ja) 2016-08-23
JP2013527225A (ja) 2013-06-27
CN102939104A (zh) 2013-02-20
WO2011151726A3 (en) 2012-02-02
EP2575873A2 (en) 2013-04-10
AU2011262312A1 (en) 2012-12-20
EA201291404A1 (ru) 2013-05-30
WO2011151726A2 (en) 2011-12-08
NZ603863A (en) 2014-09-26
AU2011262312B2 (en) 2015-05-28
KR20130081659A (ko) 2013-07-17
PL2575873T3 (pl) 2016-06-30
ES2564096T3 (es) 2016-03-17
CA2801151A1 (en) 2011-12-08
BR112012030616A2 (pt) 2017-03-01
EP2575873B1 (en) 2015-12-30
US20130243841A1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
PL2575873T3 (pl) Zatężanie i liofilizacja antygenów szczepionkowych grypy
IL262123A (en) Influenza virus vaccines and their uses
HK1245128A1 (zh) 針對人腸道病毒的抗原及疫苗
IL261204A (en) Influenza virus vaccines and their use
HK1199211A1 (en) Influenza virus vaccines and uses thereof
EP2552479A4 (en) INFLUENZA VIRUS VACCINES AND USES THEREOF
ZA201502991B (en) Disubstituted amino acids and methods of preparation and use thereof
HK1204261A1 (en) Immunogenic wt-1 peptides and methods of use thereof wt-1
EP2536425A4 (en) VACCINES FOR USE IN PROPHYLAXIS AND TREATMENT OF INFLUENZA AVIRUS DISEASE
HUE051711T2 (hu) Influenzavakcina antigénjeinek koncentrálása liofilizálás nélkül
HK1203523A1 (en) Computationally optimized broadly reactive antigens for human and avian h5n1 influenza h5n1
EP2726097A4 (en) HERPES VIRUS VACCINE AND METHOD OF USE
SG10201503450WA (en) Vaccine against beta-herpesvirus infection and use thereof
EP2621540A4 (en) SYNTHESIS PRODUCTS OF ANTIGEN CONSENSUS AND VACCINES MADE THEREFROM, AND METHODS OF USING THE SAME TO TREAT MALARIA
EP2897639A4 (en) IMPROVED VACCINE COMPOSITIONS AND METHODS OF USE
EP2442826A4 (en) INFLUENZA VACCINE, COMPOSITION, AND METHODS OF USE
ZA201205824B (en) Vaccine vectors and methods of enhancing immune responses
EP2632941A4 (en) RECOMBINANT HEMAGGLUTININE PROTEIN OF THE INFLUENZA VIRUS AND VACCINE THEREWITH
HK1201283A1 (en) Influenza c virus and vaccine
EP2739306A4 (en) OPTIMIZED ANTIGENS OF PNEUMOCYSTOSIS AND THEIR USE
IL221337A0 (en) Vaccine compositions and methods of use thereof
GB201003332D0 (en) Efficient preparation of combination vaccines
SG10201403219XA (en) Influenza Vaccine, Composition, And Methods Of Use